Showing results (101-110 of 125) with videos related to

Sort By:
Pageof 13
Bioengineered|April 27, 2023
Role of ascomycete and basidiomycete fungi in meeting established and emerging sustainability opportunities: a reviewWan Hanna Melini Wan Mohtar, Wan Abd Al Qadr Imad Wan-Mohtar, Afnan Ahmadi Zahuri, et al.
BMC Evolutionary Biology|March 25, 2017
Surface layer proteins from virulent Clostridium difficile ribotypes exhibit signatures of positive selection with consequences for innate immune responseMark Lynch, Thomas A Walsh, Izabela Marszalowska, et al.
Molecular Cancer|May 13, 2009
Identification of the B-Raf/Mek/Erk MAP kinase pathway as a target for all-trans retinoic acid during skin cancer promotionSatish B Cheepala, Weihong Yin, Zanobia Syed, et al.
The Journal of Nutritional Biochemistry|May 6, 2014
Conjugated linoleic acid suppresses dendritic cell activation and subsequent Th17 responsesEve Draper, Joseph DeCourcey, Sarah C Higgins, et al.
British Journal of Haematology|May 30, 2018
Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 studySundar Jagannath, Jacob Laubach, Ellice Wong, et al.
Antimicrobial Agents and Chemotherapy|February 15, 2012
Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaquesR Karl Malcolm, Ronald S Veazey, Leslie Geer, et al.
British Journal of Haematology|July 20, 2016
Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myelomaMaría-Victoria Mateos, Miguel Granell, Albert Oriol, et al.
Clinical and Vaccine Immunology : CVI|July 17, 2015
Profiling Humoral Immune Responses to Clostridium difficile-Specific Antigens by Protein Microarray AnalysisOla H Negm, Mohamed R Hamed, Elizabeth M Dilnot, et al.
International Journal of Molecular Sciences|May 14, 2025
Identification of eccDNA in Extracellular Vesicles Derived from Human Dermal Fibroblasts Through Nanopore SequencingBianca Simonassi-Paiva, Julia Alves Luz, Julia Hellena Ribeiro, et al.
Cancer Chemotherapy and Pharmacology|December 13, 2006
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft modelsYong S Chang, Jalila Adnane, Pamela A Trail, et al.
Pageof 13